The Treatment of Tuberculosis
|
|
- Beatrix Richards
- 7 years ago
- Views:
Transcription
1 The Treatment of Tuberculosis
2 Treating TB Old concepts Nutritional support Fresh Air, elevation, caves Sanatoriums Weimar Exercise Surgical Death rate in 1900 was 194/100K
3 British Sanatorium 1880s
4 a Denver sanatorium in the 1920s
5 Before 1940s: open air (sanatorium) 1946: streptomycin 1952: isoniazid 1970: rifampin Treatment
6 The aims of treatment of TB are: to cure the patient to prevent death from active TB or its late effects to prevent relapse of TB to decrease transmission of TB to others to prevent the development of acquired drug resistance It is vital to achieve these aims while preventing the selection of resistant bacilli in infectious patients.
7 First Line Anti-Tuberculosis Drugs Isoniazid (INH, H) Rifampicin (RIF, R) Pyrazinamide (PZA, Z) Ethambutol (EMB, E) Streptomycin (SM, S)
8 Modern TB Chemotherapy INH kills rapidly growing organisms and dormant organisms PZA kills TB bacilli inside the macrophage and cavities RIF and PZA kill slowly growing organisms sterilizing activity INH, RIF and EMB protect each other from development of resistance
9 Activities of Antituberculosis Drugs Drug Early bactericidal activity Preventing drug resistance Sterilizing activity Isoniazid Rifampicin Pyrazinamide Streptomycin Ethambutol Highest ++++ High +++ Intermediate ++ Low +
10 Group 1. First-line oral antituberculosis drugs Isoniazid - H Rifampicin - R Ethambutol - E Pyrazinamide - Z Rifabutin - Rfb Rifapentine - Rpt Group 1 anti-tb drugs, the most potent and best tolerated, should be used if there is good laboratory evidence and clinical history that suggests that a drug from this group is effective. For patients with strains resistant to low concentrations of isoniazid but susceptible to higher concentrations, the use of high-dose isoniazid may have some benefit Rifabutin and Rifapentine have similar microbiological activity as rifampicin
11 Group 2. Injectable anti-tb drugs (injectable agents or parental agents) Streptomycin - S Kanamycin - Km Amikacin - Am Capreomycin Cm All patients should receive a second-line Group 2 injectable agent in the intensive phase of MDR-TB treatment unless resistance is documented or highly suspected. Either kanamycin, amikacin or capreomycin can be used as a first choice if all meet the criteria of likely to be effective There are high rates of streptomycin resistance in strains of MDR-TB; therefore, streptomycin is not considered a second-line anti-tb injectable agent
12 Group 3. Fluoroquinolones Levofloxacin - Lfx Moxifloxacin - Mfx Gatifloxacin - Gfx Fluoroquinolones are often the most effective anti- TB drugs in an MDR-TB regimen All MDR-TB patients should be treated using latergeneration fluoroquinolones levofloxacin or moxifloxacin
13 Group 4. Oral bacteriostatic second-line antituberculosis drugs Ethionamide - Eto Prothionamide - Pto Cycloserine - Cs Terizidone - Trd Para-aminosalicylic acid - PAS Para-aminosalicylate sodium - PAS-Na Group 4 drugs are added on the basis of estimated susceptibility, drug history, efficacy, adverse effects profile and cost
14 Group 5. Group 5 drugs are not recommended by WHO for routine use in MDR-TB treatment Bedaquiline - Bdq Delamanid - Dlm Linezolid - Lzd Clofazimine - Cfz Amoxicillin/clavulanate - Amx/Clv Imipenem/cilastatin - Ipm/Cln Meropenem - Mpm High-dose isoniazid - High dose H Thioacetazone - T Clarithromycin - Clr
15 Group 5 Group 5 drugs are not recommended by WHO for routine use in MDR-TB treatment Although all of them have demonstrated some activity at least in vitro or in animal models, the quality of the evidence of their efficacy and safety in humans for the treatment of drug-resistant TB varies Most of these drugs are, with the exception of bedaquiline and delamanid, not registered for treatment of MDR-TB making their use off-label However, they remain as options in cases where adequate regimens are impossible to design with medications from Groups 1 4 If a situation requires the use of Group 5 drugs, often experts will recommend using two to three drugs from the group given the limited knowledge of efficacy
16 New Drugs in TB Treatment Bedaquiline, formerly TMC207, is a new diarylquinoline antibiotic with specific activity against Mycobacterium tuberculosis and several nontuberculous mycobacteria It acts by inhibiting ATP synthase, interfering with the energy generation needed by the bacterial cell Based on clinical evaluations for safety, tolerability and efficacy, bedaquiline has recently received accelerated approval for the treatment of pulmonary multidrug-resistant TB in adults
17 New Drugs in TB Treatment Delamanid (OPC-67683), a nitro-dihydroimidazooxazole derivative, is a new antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis Delamanid was associated with an increase in sputum-culture conversion at 2 months among patients with multidrug-resistant tuberculosis
18 Second-line Drugs Increased treatment difficulties Expensive,unavailable More side effects Difficult Ab penetration Longer treatment Controversy Standard treatments Everything it takes
19 Determining the Case Definition Bacteriology History of TB Site of Disease Smear-negative Pulmonary NO New Smear-positive Extra-pulmonary Severity of Disease TB CASES YES Return after default Relapse Failure
20 New case new, smear-positive tuberculosis cases new smear-negative cases with extensive parenchymal lesions new cases with severe extrapulmonary tuberculosis (disseminated, meningeal, pericardial, peritoneal, bilateral pleural, spinal, intestinal and genitourinary)! A new case is defined as a patient who has never previously been treated for tuberculosis or who has received treatment for less than one month.
21 Retreatment smear-positive cases who have already received treatment for at least one month in the past who need to receive re-treatment. Among these patients three groups can be distinguished: Relapses patients who have been treated and declared cured, but whose smear examinations are once again positive Failures patients whose smear examinations have remained positive or have once again become positive 5 or more months after starting treatment Return after interruption patients who return to the health centre smear-positive after interrupting treatment for more than two consecutive months
22 Chronic cases chronic cases defined as smearpositive cases of pulmonary tuberculosis who have already received a supervised re-treatment regimen Resistant form of TB
23 Treatment regimens initial intensive phase, which rapidly reduces the bacterial population the initial intensive phase consists of at least four drugs continuation phase, which destroys those bacteria that remain the continuation phase is given for 4 months if the two most bactericidal drugs, isoniazid and rifampicin, are used, and for 6 months if isoniazid and a bacteriostatic drug are used
24 Treatment schedules recommended by tuberculosis case Tuberculosis case Recommended treatment schedule Initial phase Continuation phase - New case of smearpositive PTB - Severe forms of smearnegative PTB - Severe extrapulmonary tuberculosis 2 EHRZ (SHRZ) 2 EHRZ (SHRZ) 2 EHRZ (SHRZ) 6 HE or 6 TH 4 HR 4 HR
25 Treatment of Active TB Four drug regimen for first 2 months: INH 300 mg Rifampin 600 mg PZA mg/kg Ethambutol mg/kg or streptomycin 15 mg/kg Two drug regimen for next 4 months: INH and rifampin
26 Treatment schedules recommended by tuberculosis case Tuberculosis case Recommended treatment schedule Initial phase Continuation phase Smear-positive pulmonary tuberculosis: Relapse Failure Return after interruption 2 SHRZE/1 HRZE 5 HRE
27 Ongoing Diagnostic Monitoring Monthly sputum collection (until two negative smears) Look for smear positive cases after initial two months of therapy Liver function tests if abnormalities on screening or risk factors for hepatitis
28 Monitoring the efficacy of treatment with bacteriological examinations At the end of the initial phase sputum conversion is observed in most cases. If the patient is still smear-positive the initial phase should be prolonged by 1 month At the end of the 4th month for 6-month regimens, and at the end of the 5th month for 8-month regimens During the last month (at the 6th or 8th month, depending on the regimen). These smear examinations confirm the success or failure of the treatment In the case of extrapulmonary tuberculosis, followup is essentially clinical
29 Treatment outcome Cured: at least two negative examinations (one after the end of the initial intensive phase of treatment and another during the last month of treatment). Treatment completed: the patient has received a full course of treatment but has not undergone the necessary bacteriological examinations. Failure: still positive or positive once again after the 5th month of treatment.
30 Treatment outcome Died: whatever the cause of death. Transferred out: the patient has been transferred to another health centre while on treatment but the final outcome of the treatment is not known at the centre where the patient was registered. Where the final outcome is known, this should be recorded, rather than transferred out. Defaulted: the patient has not turned up to collect drugs for more than 2 months since the last visit.
31 Problems of TB therapy Toxicity e.g. liver Multiple therapy Prolonged treatment Drug interactions e.g. anti HIV drugs
32 Directly observed treatment means that an observer watches the patient swallowing their tablets, in a way that is sensitive and supportive to the patient's needs. This ensures that a TB patient takes the right antituberculosis drugs, in the right doses, at the right intervals
33 Directly Observed Therapy (DOT) Health care worker watches patient swallow each -Dose of medication -Every pill, every day -Self-administered is NOT DOT REMEMBER DOT for all patients on all regimens NO exceptions
34 Directly Observed Therapy (DOT) DOT can lead to reductions in relapse and acquired drug resistance Use DOT with other measures to promote adherence DOT is the key to CURE
35 Directly Observed Therapy (DOT)
36
37 What is DOTS? D.O.T.S stands for Directly-Observed Treatment Short Course It is a comprehensive strategy endorsed by the World Health Organization (WHO) and International Union Against Tuberculosis and Lung Diseases (IUATLD) to detect and cure TB patients
38 DOTS PLUS A case management strategy under development, designed to manage MDR- TB using second line drugs within the DOTS strategy in low and middle income countries. To prevent further development and spread of MDR-TB.
39 Drug Resistance
40 Definition of Drug Resistant TB Confirmed mono-resistance: tuberculosis in patients whose infecting isolates of M. tuberculosis are confirmed to be resistant in vitro to one first-line antituberculosis drug
41 Definition of Drug Resistant TB Confirmed poly-resistance: tuberculosis in patients whose infecting isolates are resistant in vitro to more than one first-line antituberculosis drug, other than both isoniazid and rifampicin
42 Definition of Drug Resistant TB Multi-Drug Resistance (MDR): resistance to at least both isoniazid and rifampicin extensive-drug Resistance (XDR): resistance to any fluoroquinolone, and at least one of three second-line injectable drugs (capreomycin, kanamycin and amikacin), in addition to multidrug resistance Treatment based on susceptibilities Higher risk of mortality
43 Drug Resistance Definitions Primary drug resistance Applies to previously untreated patients who are found to have drug- resistant organisms, presumably because they have been infected from an outside source of resistant Mycobacterium tuberculosis. Acquired drug resistance Applies to patients who initially have drugsusceptible bacteria that become drugresistant due to inadequate, inappropriate, or irregular treatment or, more importantly, because of non-adherence in drug taking.
44 Causes of Resistance Irregular Self Administration with Failure to closely supervise Care of patients by non specialists Increased immigration
45 Persons at Increased Risk for Drug Resistance History of treatment with TB drugs Contacts of persons with drug resistant TB Smears or cultures remain positive despite 2 months of TB treatment Received inadequate treatment regimens for >2 weeks
46 Inadequate Treatment Multi-factorial Lack of adherence/intermittent or interrupted therapy Malabsorption Inappropriate regimens; to properly treat TB one must always add at least two drugs to a failing regimen Sub-therapeutic dosing Expired or substandard drugs
47 Standardized treatment Regimens are designed on the basis of representative DRS data of specific treatment categories However, suspected MDR-TB should always be confirmed by DST results whenever possible. All patients in a defined group or category receive the same treatment regimen
48 Empirical treatment Each regimen is individually designed on the basis of the previous history of antituberculosis treatment and with the help of representative DRS survey data Commonly, an empirical treatment is adjusted in each patient when his or her DST results become available
49 Individualized treatment Each regimen is designed based on the patient s past history of TB treatment and individual DST results
50 The basic principles Regimens should be based on the history of drugs taken by the patient Regimens should consist of at least four drugs with either certain, or almost certain, effectiveness Drugs are administered at least six days a week An injectable agent (an aminoglycoside or capreomycin) is used for a minimum of 6 months Treatment is for a minimum duration of 18 months beyond conversion Each dose is given as DOT throughout the treatment
51 Step 1 Begin with any First line agents to Which the isolate is Susceptible Use any available First-line drugs PLUS One of these Fluoroquinolones PLUS One of these Injectable agents Add a Fluoroquinolone And an injectable Drug based on susceptibilities Pyrazinamide Ethambutol Levofloxacin Moxifloxacin Amikacin Capreomycin Streptomycin Kanamycin BS
52 Step 1 Begin with any First line agents to Which the isolate is Susceptible Use any available First-line drugs PLUS One of these Fluoroquinolones PLUS One of these Injectable agents Add a Fluoroquinolone And an injectable Drug based on susceptibilities Pyrazinamide Ethambutol Levofloxacin Moxifloxacin Amikacin Capreomycin Streptomycin Kanamycin Step 2 Add 2 nd line drugs until you have 4-6 drugs to which isolate is susceptible (which have not been used previously) Pick one or more of these Oral second line drugs Cycloserine Ethionamide PAS
53 Step 1 Begin with any First line agents to Which the isolate is Susceptible Use any available First-line drugs PLUS One of these Fluoroquinolones PLUS One of these Injectable agents Add a Fluoroquinolone And an injectable Drug based on susceptibilities Pyrazinamide Ethambutol Levofloxacin Moxifloxacin Amikacin Capreomycin Streptomycin Kanamycin Step 2 Add 2 nd line drugs until you have 4-6 drugs to which isolate is susceptible (which have not been used previously) Step 3 Pick one or more of these Oral second line drugs Cycloserine Ethionamide PAS Consider use of these If there are not 4-6 drugs available consider 3 rd line in consult with MDRTB experts Third line drugs Imipenem Linezolid Macrolides Amoxicillin/Clavulanate BS
54 Treatment of Active TB INH resistant TB: Rifampin, PZA, and ethambutol for 6 months Rifampin resistant TB: INH, PZA, and streptomycin for 9 months or INH and ethambutol for 18 months MDR/XDR TB: Based on susceptibility patterns
55 Treatment of MDR TB in RM Standardized treatment (WHO): Initial phase - 6 months: Cm, Eth, Z, Lfx, Cs,(PAS) Continuation phase 18 months: Eth, Z, Lfx, Cs,(PAS) DOT
56 Consequences of MDR Delay in diagnosis Treatment duration extended 18 to 24 mo. Second line drugs Effectiveness decreases Toxicity increases Expensive to treat Community transmission
57 How we can prevent MDR TB Initial treatment with standardized regimens (HRZE) Directly observed therapy (DOT) Drug susceptibility testing for all retreatment cases Infection control precautions Monitor drug resistance through surveys Effective contact management
58 Interventions to prevent drug-resistant TB 1. Early detection and high quality treatment of drug-susceptible TB 2. Early detection and high quality treatment of drug-resistant TB 3. Effective implementation of infection control measures 4. Strengthening and regulation of health systems 5. Addressing underlying risk factors and social determinants
59 XDR= HR + 1 FQ + 1 Injectable (KM or AMK or CM) 1 st -line oral INH RIF PZA EMB (Rfb) Injectables SM KM AMK CM Fluoroquinolones Cipro Oflox Levo Moxi (Gati) Oral bacteriostatic 2nd line ETA/PTA PASA CYS Unclear efficacy Not routinely recommended, efficacy unknown, e.g., amoxacillin/clavulanic acid, clarithromycin, clofazamine, linezolid, inmipenem/cilastatin, high dose isonizid 59
60 Drug treatment of sensitive TB
61 Drug treatment of MDR TB
62 Drug treatment of XDRTB
63 Treatment options for XDR?
64
65 Tuberculosis anywhere is Tuberculosis everywhere
66 ???????????
67
Management of Tuberculosis: Indian Guidelines
Chapter 105 Management of Tuberculosis: Indian Guidelines Kuldeep Singh Sachdeva INTRODUCTION Tuberculosis (TB) is an infectious disease caused predominantly by Mycobacterium tuberculosis and among the
More informationDr Malgosia Grzemska Global TB programme, WHO/HQ Meeting of manufacturers Copenhagen, Denmark, 23-26 November 2015
TB burden and treatment guidelines Dr Malgosia Grzemska Global TB programme, WHO/HQ Meeting of manufacturers Copenhagen, Denmark, 23-26 November 2015 Outline Latest epidemiological data Global programme
More informationMODULE THREE TB Treatment. Treatment Action Group TB/HIV Advocacy Toolkit
MODULE THREE TB Treatment Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be covered TB treatment fundamentals Treatment of TB infection and disease TB treatment research Advocacy issues 2 Section
More informationChapter 6 Treatment of Tuberculosis Disease
Chapter 6 Treatment of Tuberculosis Disease Table of Contents Chapter Objectives.... 139 Introduction.... 141 Treatment and Monitoring Plan.... 143 Adherence Strategies... 143 TB Disease Treatment Regimens....
More informationRecent Advances in The Treatment of Mycobacterium Tuberculosis
Recent Advances in The Treatment of Mycobacterium Tuberculosis Dr Mohd Arif Mohd Zim Senior Lecturer & Respiratory Physician Faculty of Medicine, Universiti Teknologi MARA mohdarif035@salam.uitm.edu.my
More informationThe endtb Project: Expanding New Drugs for TB PARTNERS IN HEALTH (PIH) MÉDECINS SANS FRONTIÈRES (MSF) INTERACTIVE RESEARCH & DEVELOPMENT (IRD)
The endtb Project: Expanding New Drugs for TB PARTNERS IN HEALTH (PIH) MÉDECINS SANS FRONTIÈRES (MSF) INTERACTIVE RESEARCH & DEVELOPMENT (IRD) April 29 th, 2015 Geneva, Switzerland Summary of endtb endtb
More informationMANAGEMENT OF TUBERCULOSIS
MANAGEMENT OF TUBERCULOSIS Dean B. Ellithorpe, M.D. Clinical Professor of Medicine Section of Pulmonary Diseases, Critical Care and Environmental Medicine Tulane University School of Medicine INTRODUCTION
More informationTB Prevention, Diagnosis and Treatment. Accelerating advocacy on TB/HIV 15th July, Vienna
TB Prevention, Diagnosis and Treatment Accelerating advocacy on TB/HIV 15th July, Vienna Diagnosis Microscopy of specially stained sputum is the main test for diagnosing TB (1 2 days) TB bacilli seen in
More informationTuberculousmeningitis: what is the best treatment regimen?
Tuberculousmeningitis: what is the best treatment regimen? H S Schaaf Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University
More informationDefinitions and reporting framework for tuberculosis 2013 revision (updated December 2014)
Definitions and reporting framework for tuberculosis 2013 revision (updated December 2014) Cover photos: WHO Photo Library Top, Nepal (C. Black); middle, Afghanistan (C. Black); bottom, China (S. Lim)
More informationTreatment of DR-TB in children and preventive therapy for children exposed to DR-TB H Simon Schaaf
Treatment of DR-TB in children and preventive therapy for children exposed to DR-TB H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Treatment of Latent Tuberculosis Infection and Tube rc ulos is Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National
More informationTB preventive therapy in children. Introduction
TB preventive therapy in children H S Schaaf Department of Paediatrics and Child Health, and Desmond Tutu TB Centre Stellenbosch University, and Tygerberg Children s Hospital Introduction Children are
More informationChapter Four: Treatment of Tuberculosis Disease
Chapter Four: Treatment of Tuberculosis Disease The standard of tuberculosis (TB) treatment in Los Angeles County (LAC) is to initiate an appropriate chemotherapeutic regimen along with Directly Observed
More informationDIRECTLY OBSERVED TREATMENT SHORT-COURSE (DOTS)
DIRECTLY OBSERVED TREATMENT SHORT-COURSE (DOTS) Protocol for Tuberculosis Demonstration Projects in Russia U.S. Centers for Disease Control and Prevention and U.S. Agency for International Development
More informationMANAGEMENT OF DRUG-RESISTANT TUBERCULOSIS POLICY GUIDELINES
MANAGEMENT OF DRUG-RESISTANT TUBERCULOSIS POLICY GUIDELINES 2010 FOREWORD The following policy guidelines are intended for use by health care professionals involved in the complex and difficult task of
More informationTreatment. Introduction... 32. Individualized Regimens.. 33. Selection and Dosing of Drugs... 41. Administration of the Regimen...
Treatment 3 Introduction............ 32 Individualized Regimens.. 33 Monoresistance......... 33 Polyresistance.......... 34 Multidrug Resistance..... 35 Extensive Drug Resistance 39 Selection and Dosing
More information1 : 9. Rajendra Prasad, Etawah
MANAGEMENT OF Drug resistant and multidrug resistant tuberculosis 1 : 9 Rajendra Prasad, Etawah Introduction Drug resistant tuberculosis (DR-TB) has been reported since the early days of introduction of
More informationGuideline. Treatment of tuberculosis in pregnant women and newborn infants. Version 3.0
Guideline Treatment of tuberculosis in pregnant women and newborn infants Version 3.0 Key critical points The decision to treat tuberculosis (TB) in pregnancy must consider the potential risks to mother
More informationCurrent trends in chemotherapy of tuberculosis
Review Article Indian J Med Res 120, October 2004, pp 398-417 Current trends in chemotherapy of tuberculosis M.S. Jawahar Tuberculosis Research Centre (ICMR), Chennai, India Received August 28, 2003 After
More informationEmerging Infectious Disease (4): Drug-Resistant Tuberculosis
S67 Drug-Resistant Tuberculosis Emerging Infectious Disease (4): Drug-Resistant Tuberculosis Chi-Fang You, MD; Han-Ping Ma, MD; Tzong-Luen Wang, MD, PhD; Aming Chor-Min Lin, MD Abstract Before the discovery
More informationRevised National Tuberculosis Control Programme (RNTCP) Dr. NAVPREET
Revised National Tuberculosis Control Programme (RNTCP) Dr. NAVPREET Assistant Prof., Deptt. of Community Medicine GMCH Chandigarh Problem Statement of TB in India India accounts for nearly 1/4 th of global
More informationClinical Scenarios In Childhood TB. Josefina Cadorna Carlos M.D., FPPS, FPIDSP, FSMID Associate Professor of Pediatrics U E R M M M C
Clinical Scenarios In Childhood TB Josefina Cadorna Carlos M.D., FPPS, FPIDSP, FSMID Associate Professor of Pediatrics U E R M M M C Objectives: To present different commonly encountered clinical scenarios
More informationREPUBLIC OF UGANDA UGANDA NATIONAL GUIDELINES FOR THE PROGRAMMATIC MANAGEMENT OF DRUG RESISTANT TUBERCULOSIS
REPUBLIC OF UGANDA UGANDA NATIONAL GUIDELINES FOR THE PROGRAMMATIC MANAGEMENT OF DRUG RESISTANT TUBERCULOSIS THE REPUBLIC OF UGANDA MINISTRY OF HEALTH THE NATIONAL TUBERCULOSIS AND LEPROSY PROGRAMME MINISTRY
More informationTreatment of tuberculosis. guidelines. Fourth edition
Treatment of tuberculosis guidelines Fourth edition Treatment of tuberculosis Guidelines Fourth edition WHO Library Cataloguing-in-Publication Data: Treatment of tuberculosis: guidelines 4th ed. WHO/HTM/TB/2009.420
More informationMain objectives in TB Rx
Treatment of Tuberculosis in Children HS Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health Stellenbosch University Main objectives in TB Rx To rapidly kill most bacilli in order
More informationU.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention National Center for HIV, STD, and TB Prevention Division of Tuberculosis Elimination Public
More informationTuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges
Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges John B. Kaneene, DVM, MPH, PhD University Distinguished Professor of Epidemiology Director, Center for Comparative Epidemiology
More informationTuberculosis in Children and Adolescents
Tuberculosis in Children and Adolescents Ritu Banerjee, MD, Ph.D TB Clinical Intensive April 8, 2015 2014 MFMER slide-1 Disclosures None 2014 MFMER slide-2 Objectives Describe the epidemiology of pediatric
More informationTuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University
Tuberculosis And Diabetes Dr. hanan abuelrus Prof.of internal medicine Assiut University TUBERCULOSIS FACTS More than 9 million people fall sick with tuberculosis (TB) every year. Over 1.5 million die
More informationTreatment of Tuberculosis
Morbidity and Mortality Weekly Report Recommendations and Reports June 20, 2003 / Vol. 52 / No. RR-11 Treatment of Tuberculosis American Thoracic Society, CDC, and Infectious Diseases Society of America
More informationGuideline. Treatment of tuberculosis in renal disease. Version 3.0
Guideline Treatment of tuberculosis in renal disease Version 3.0 Key critical points Renal failure is recognised as a risk factor for developing tuberculosis. Renal failure is recognised as a risk factor
More informationNew anti-tuberculosis drugs and regimens: 2015 update
REVIEW TUBERCULOSIS New anti-tuberculosis drugs and regimens: 2015 update Lia D Ambrosio 1,6, Rosella Centis 1,6, Giovanni Sotgiu 2, Emanuele Pontali 3, Antonio Spanevello 4,5 and Giovanni Battista Migliori
More informationCDHS/CTCA JOINT GUIDELINES Guidelines for the Treatment of Active Tuberculosis Disease. Table of Contents
Treatment of Tuberculosis Disease CDHS/CTCA JOINT GUIDELINES Table of Contents I. Basic Principles 1 A. Organization and Treatment 1 B. Treatment 1 C. Clinical Management Issues 2 II. Diagnosis 2 III.
More informationGeneral Information on Tuberculosis
General Information on Tuberculosis ON THE MOVE AGAINST TUBERCULOSIS: Transforming the fi ght towards elimination World TB Day 2011 SAARC Tuberculosis & HIV/AIDS Centre GPO Box No 9517, Kathmandu, Nepal
More informationMinistry of Public Health and Sanitation GUIDELINES FOR THE MANAGEMENT DRUG RESISTANT TUBERCULOSIS IN KENYA
Ministry of Public Health and Sanitation GUIDELINES FOR THE MANAGEMENT OF DRUG RESISTANT TUBERCULOSIS IN KENYA DIVISION OF LEPROSY, TUBERCULOSIS AND LUNG DISEASE March 2010 Table of Contents Table of Contents...
More informationPolicy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs World Health Organization Geneva 2008
Policy guidance on drugsusceptibility testing (DST) of secondline antituberculosis drugs World Health Organization Geneva 2008 WHO/HTM/TB/2008.392 1 World Health Organization 2008 All rights reserved.
More informationTreatment of Tuberculosis
Treatment of Tuberculosis 1a Taking TB Treatment 2 Learning outcomes Describe the use of TB case definitions & the management of TB patients Successfully treat TB using the appropriate regimen for the
More informationScreening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults)
Screening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults) H S Schaaf Department of Paediatrics and Child Health, and Desmond Tutu TB Centre Stellenbosch University, and Tygerberg
More informationPregnancy and Tuberculosis. Information for clinicians
Pregnancy and Tuberculosis Information for clinicians When to suspect Tuberculosis (TB)? Who is at risk of TB during pregnancy? Recent research suggests that new mothers are at an increased risk of TB
More informationMaximizing Rifamycins
Maximizing Rifamycins Charles A. Peloquin, Pharm.D. Director Infectious Disease Pharmacokinetics Laboratory Professor, College of Pharmacy & The Emerging Pathogens Institute University of Florida Page
More informationTREATMENT OF TUBERCULOSIS: GUIDELINES FOR NATIONAL PROGRAMMES THIRD EDITION
WHO/CDS/TB/2003.313 TREATMENT OF TUBERCULOSIS: GUIDELINES FOR NATIONAL PROGRAMMES THIRD EDITION World Health Organization - Geneva 2003 First edition, 1993 Second edition, 1997 Third edition, 2003 TREATMENT
More informationNew York City Department of Health Protocols for Latent TB Infection Treatment
New York City Department of Health Protocols for Latent TB Infection Treatment CONTENT A. Medical evaluation for latent TB infection (LTBI) treatment 1. Medical history and physical examination 2. Chest
More informationTHE MSF CAMPAIGN FOR ACCESS TO ESSENTIAL MEDICINES THE INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE
MSF TB print 3/22/11 5:27 PM Page 1 MSF TB print 3/22/11 5:27 PM Page 2 THE MSF CAMPAIGN FOR ACCESS TO ESSENTIAL MEDICINES In 1999, in the wake of Médecins Sans Frontières (MSF) being awarded the Nobel
More informationSummary of the risk management plan (RMP) for Sirturo (bedaquiline)
EMA/16634/2014 Summary of the risk management plan (RMP) for Sirturo (bedaquiline) This is a summary of the risk management plan (RMP) for Sirturo, which details the measures to be taken in order to ensure
More informationChapter 5 Treatment for Latent Tuberculosis Infection
Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI.... 112 LTBI Treatment Regimens.... 118 LTBI
More informationNew Jersey Department of Health and Senior Services. Standards of Care for Tuberculosis Disease and Latent TB Infection
New Jersey Department of Health and Senior Services Standards of Care for Tuberculosis Disease and Latent TB Infection Tuberculosis Medical Advisory Board March 2007 Table of Contents Standard # 1: Diagnosis
More informationRESEARCH AGENDA ON DRUG RESISTANT TUBERCULOSIS With A Focus On Scaling-up Programmes
RESEARCH AGENDA ON DRUG RESISTANT TUBERCULOSIS With A Focus On Scaling-up Programmes Background The Working Group on MDR-TB is an inter-institutional working group involving institutions/agencies and experts
More informationMonitoring Patients. Initial Evaluation... 128. Documentation... 129. General Monitoring... 129. Specific Monitoring... 130. Monitoring Tools...
6 Monitoring Patients Initial Evaluation........ 128 Documentation......... 129 General Monitoring..... 129 Specific Monitoring..... 130 Drug Administration..... 130 Absorption, Interactions. 130 Weight,
More informationPEDIATRIC TUBERCULOSIS. Hot topics / Unresolved issues in Clinical Practice
PEDIATRIC TUBERCULOSIS Hot topics / Unresolved issues in Clinical Practice Ann M. Loeffler, M.D. Legacy Emanuel Children s Hospital Portland, OR Faculty Consultant Francis J. Curry National TB Center February
More informationClinical description 2 Laboratory test for diagnosis 3. Incubation period 4 Mode of transmission 4 Period of communicability 4
Tuberculosis Contents Epidemiology in New Zealand 2 Case definition 2 Clinical description 2 Laboratory test for diagnosis 3 Case classification 3 Spread of infection 4 Incubation period 4 Mode of transmission
More informationGuidelines for the programmatic management of drug-resistant tuberculosis
Stop TB Department World Health Organization 20 Avenue Appia, 1211 Geneva 27, Switzerland Web site: www.who.int/tb Fax: +41 22 791 4285 Information Resource Centre HTM/STB: tbdocs@who.int ISBN 92 4 154695
More informationAmerican Thoracic Society Documents
American Thoracic Society Documents American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis This Official Joint Statement
More informationTB CARE EARLY DETECTION AND PREVENTION OF TUBERCULOSIS (TB) IN CHILDREN. Risk factors in children acquiring TB:
EARLY DETECTION AND PREVENTION OF TUBERCULOSIS (TB) IN CHILDREN Risk factors in children acquiring TB: Children living in the same household as a lung TB patient (especially children under 5) Children
More informationGuideline. Treatment of tuberculosis in adults and children Version 2.1 July 2015
Guideline Treatment of tuberculosis in adults and children Version 2.1 July 2015 Contents What this guideline covers:... 1 What this guideline does not cover:... 1 Standard regimens for pulmonary tuberculosis...
More informationTUBERCULOSIS CONTROL INDIA
TUBERCULOSIS CONTROL INDIA In terms of population coverage, India now has the second largest DOTS (Directly Observed Treatment, Short course) programme in the world. However, India's DOTS programme is
More informationTUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY. Stephanie N. Lin MD 2/12/2016
TUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY Stephanie N. Lin MD 2/12/2016 Epidemiology of TB 9.6 million new cases in 2014 12% of them are in HIV positive patients 1.5 million deaths in 2014 ~646
More informationTreatment of TB a pharmacy perspective
Treatment of TB a pharmacy perspective Colm McDonald, Antimicrobial Stewardship Pharmacist (Acting) National TB Conference, St. James s Hospital 6 th May 2011 Overview of presentation Role of the pharmacist
More informationNON-COMMERCIAL CULTURE AND DRUG-SUSCEPTIBILITY TESTING METHODS FOR SCREENING OF PATIENTS AT RISK OF MULTI-DRUG RESISTANT TUBERCULOSIS
NON-COMMERCIAL CULTURE AND DRUG-SUSCEPTIBILITY TESTING METHODS FOR SCREENING OF PATIENTS AT RISK OF MULTI-DRUG RESISTANT TUBERCULOSIS - POLICY STATEMENT - July 2010 TABLE OF CONTENTS 1. Background... 1
More informationMANAGEMENT OF DRUG-RESISTANT TUBERCULOSIS
MANAGEMENT OF DRUG-RESISTANT TUBERCULOSIS POLICY GUIDELINES (UPDATED - JANUARY 2013) Table of Contents Foreword...VIII Acknowledgements...IX Abbreviations...X Anti-Tuberculosis Drug Abbreviations...XI
More informationManagement of a child failing first line TB treatment.
Management of a child failing first line TB treatment. Robert Gie Desmond Tutu Tuberculosis Centre Department of Paediatric and Child Health Stellenbosch University South Africa. Tygerberg Hospital Complex
More informationGUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA
GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA 2010 1 TB prophylaxis GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS Background
More informationChallenges Associated with Current and Future TB Treatment
Infectious Disorders - Drug Targets 2007, 7, 105-119 105 Challenges Associated with Current and Future TB Treatment M. Laurenzi*, A. Ginsberg and M. Spigelman The Global Alliance for TB Drug Development,
More informationTuberculosis: FAQs. What is the difference between latent TB infection and TB disease?
Tuberculosis: FAQs What is TB disease? Tuberculosis (TB) is a disease caused by bacteria (germs) that are spread from person to person through the air. TB usually affects the lungs, but it can also affect
More informationIMA Knowledge June, 2015
Tuberculosis is a major public health problem in India. Early diagnosis and complete treatment of TB is the corner-stone of TB prevention and control strategy. India's Revised National TB Control program(rntcp)
More informationAMBULATORY TREATMENT AND PUBLIC HEALTH MEASURES FOR A PATIENT WITH UNCOMPLICATED PULMONARY TUBERCULOSIS
AMBULATORY TREATMENT AND PUBLIC HEALTH MEASURES FOR A PATIENT WITH UNCOMPLICATED PULMONARY TUBERCULOSIS AN INFORMATION PAPER January 2013 AMBRX_1301 This information paper is an update of Chapter 17 of
More informationOutcomes and Use of Therapeutic Drug Monitoring in Multidrug-Resistant Tuberculosis Patients Treated in Virginia, 2009 2014
ORIGINAL ARTICLE http://dx.doi.org/10.4046/trd.2015.78.2.78 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2015;78:78-84 Outcomes and Use of Therapeutic Drug Monitoring in Multidrug-Resistant
More informationGENERAL MANNUAL FOR TUBERCULOSIS CONTROL
GENERAL MANNUAL FOR TUBERCULOSIS CONTROL National programme for Tuberculosis Control and Chest Diseases Ministry of Health Sri Lanka January 2005 GENERAL MANUAL FOR TUBERCULOSIS CONTROL Second Edition
More informationCourse on Multidrug-Resistant Tuberculosis MDR-TB
Course on Multidrug-Resistant Tuberculosis MDR-TB COURSE ON MULTIDRUG-RESISTANT TUBERCULOSIS MDR-TB World Medical Association The World Medical Association (WMA) is an international organization representing
More information12 Points of Tuberculosis (TB) Patient Education
12 Points of Tuberculosis (TB) Patient Education Transmission of TB TB is a disease caused by the TB germ. The disease is mainly in the lungs (pulmonary TB), but the germ can travel to other parts of the
More informationChapter 1 Overview of Tuberculosis Epidemiology in the United States
Chapter 1 Overview of Tuberculosis Epidemiology in the United States Table of Contents Chapter Objectives.... 1 Progress Toward TB Elimination in the United States.... 3 TB Disease Trends in the United
More informationTB Case Definitions Revision May 2011
TB Case Definitions Revision May 2011 Table of contents TABLE OF CONTENTS 1 1. BACKGROUND 3 2. CURRENT WHO DEFINITIONS OF CASES AND TREATMENT OUTCOMES 4 3. COMMENTARY ON CURRENT WHO DEFINITIONS OF CASES
More informationTreatment of Tuberculosis during Pregnancy
Treatment of Tuberculosis during Pregnancy SA HIV Clinician s Society Conference 25 September 2014 Rebecca Berhanu 1 Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University
More informationPapua New Guinea. National Tuberculosis Management Protocol. Department of Health Disease Control Branch National Tuberculosis Program
2011 Papua New Guinea National Tuberculosis Management Protocol Department of Health Disease Control Branch National Tuberculosis Program P.O. Box 807, Waigini, Port Moresby, Papua New Guinea Telephones:
More informationAMBULATORY TREATMENT AND PUBLIC HEALTH MEASURES FOR A PATIENT WITH UNCOMPLICATED PULMONARY TUBERCULOSIS
AMBULATORY TREATMENT AND PUBLIC HEALTH MEASURES FOR A PATIENT WITH UNCOMPLICATED PULMONARY TUBERCULOSIS (UPDATE 2004) Internal guidelines of the Tuberculosis & Chest Service of the Department of Health
More informationMresistant to isoniazid and rifampin. The
CASE REPORT Zafar Iqbal*, Afsar Khan**, Arshad Javaid* *Department of Pulmonology, ** Programmatic Management of Drug Resistant TB Unit, Department of Pulmonology, Adress for correspondence: Dr. Zafar
More informationMANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol)
MANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol) 1. Hepatotoxicity: In Active TB Disease a. Background: 1. Among the 4 standard anti-tb drugs,
More informationManagement of Multidrug-Resistant Tuberculosis in Children: A Field Guide
Management of Multidrug-Resistant Tuberculosis in Children: A Field Guide Photo: Justin Ide First Edition: November, 2012 This handbook is made possible by the support of the American people through the
More informationMANAGEMENT OF TUBERCULOSIS IN PRISONS: Guidance for prison healthcare teams
MANAGEMENT OF TUBERCULOSIS IN PRISONS: Guidance for prison healthcare teams Document control Title Type Author/s Management of tuberculosis in prisons: Guidance for prison healthcare teams Operational
More informationGuidelines for the programmatic management of drug-resistant tuberculosis. 2011 update
Guidelines for the programmatic management of drug-resistant tuberculosis 2011 update This guideline was developed in compliance with the process for evidence gathering, assessment and formulation of recommendations,
More informationCHAPTER 9: TREATMENT OF ACTIVE TB DISEASE
CHAPTER 9: TREATMENT OF ACTIVE TB DISEASE 9.1 Treatment Regimens....... 2 9.1.1 Standard TB Treatment Regimen......2 9.1.2 Alternate TB Treatment Regimens.3 9.2 Phases of TB Treatment....3 9.3 TB Medications
More informationTuberculosis OUR MISSION THE OPPORTUNITY
Tuberculosis OUR MISSION Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. Our Global Health Program is
More informationecompliance: Revolutionizing Tuberculosis Treatment Designed in collaboration with: Microsoft Research India & Innovators In Health 1
ecompliance: Revolutionizing Tuberculosis Treatment Designed in collaboration with: Microsoft Research India & Innovators In Health 1 Overview Operation ASHA is a non-profit bringing tuberculosis treatment
More informationQuestions and Answers About Tuberculosis
Questions and Answers About Tuberculosis 2014 Questions and Answers About Tuberculosis 2014 Questions and Answers About Tuberculosis ( TB) was written to provide information on the diagnosis and treatment
More informationSan Francisco Treatment Guidelines for Latent Tuberculosis Infection
City and County of San Francisco Department of Public Health Tuberculosis Control Unit Julie Higashi, MD, PhD Director Population Health Division Edwin M. Lee Mayor Disease Prevention and Control Branch
More informationTuberculosis Exposure Control Plan for Low Risk Dental Offices
Tuberculosis Exposure Control Plan for Low Risk Dental Offices A. BACKGROUND According to the CDC, approximately one-third of the world s population, almost two billion people, are infected with tuberculosis.
More informationHow To Treat Tuberculitis
Treatment of Tuberculosis Disease CONTENTS Introduction... 6.2 Purpose... 6.2 Policy... 6.2 Forms... 6.3 Reporting Requirements... 6.3 Basic Treatment Principles... 6.4 Treatment Regimens and Dosages...
More informationSCHEDULE No. 1: Oral solid dosage forms: Fluoroquinolones
ANNEX B/ SECTION 8: TECHNICAL SPECIFICATIONS NOTE: The estimated Global need for required below products is provided in Annex H of this ITB. Actual quantity to be ordered in 2015 can vary due to countries
More informationBest drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis José A Caminero, Giovanni Sotgiu, Alimuddin Zumla, Giovanni Battista Migliori Multidrug-resistant (MDR) and extensively
More informationX-Plain Pediatric Tuberculosis Reference Summary
X-Plain Pediatric Tuberculosis Reference Summary Introduction Tuberculosis, or TB, is a bacterial infection that causes more deaths in the world than any other infectious disease. When a child gets TB,
More informationDevelopment of New TB Drugs. Martino Laurenzi, MD, MPH 16 th Symposium Tuberculose de Muenchenwiler 22 mars 2007
Development of New TB Drugs Martino Laurenzi, MD, MPH 16 th Symposium Tuberculose de Muenchenwiler 22 mars 27 Outline of this Presentation TB treatment: past & present Role of the TB Alliance New TB drug
More informationCIRCULATED FOR COMMENTS - Feb04 DRAFT. BHIVA treatment guidelines for TB/HIV infection
BHIVA treatment guidelines for TB/HIV infection February 2004 (DRAFT) Dr Anton Pozniak Contents 1.0 Introduction 2.0 Aims of TB treatment 3.0 Treatment Regimens 4.0 Drug/drug interactions 5.0 Overlapping
More informationTreatment of Tuberculosis Disease
Treatment of Tuberculosis Disease CONTENTS Introduction... 6.2 Purpose... 6.2 Policy... 6.2 Forms... 6.3 Basic Treatment Principles... 6.4 Treatment Regimens and Dosages... 6.6 Regimens... 6.6 Dosages...
More informationDOTS STRATEGY IN INDIA
DOTS STRATEGY IN INDIA - THE CHALLENGES Prof. V.K. Arora*, Dr. Rajnish Gupta, LRS Institute of TB and Allied Diseases, Sri Aurobindo Marg, New Delhi. INTRODUCTION The DOTS strategy has emerged as a possible
More informationRevised National Tuberculosis Control Programme. DOTS-Plus Guidelines
Revised National Tuberculosis Control Programme DOTS-Plus Guidelines Central TB Division, Directorate General of Health Services, Ministry of Health & Family Welfare, Nirman Bhavan, New Delhi 110011 Revised
More informationChallenges in tuberculosis drug research and development
Challenges in tuberculosis drug research and development Ann M Ginsberg & Melvin Spigelman The present decade has seen a reawakening of tuberculosis (TB) drug research and development (R&D), spurred on
More informationAntibiotic Treatment of Tuberculosis: Old Problems, New Solutions
Antibiotic Treatment of Tuberculosis: Old Problems, New Solutions With tuberculosis and drug resistance surging, the search is on for new drugs along with better and faster ways of evaluating them Sanjay
More informationIntroduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015
Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015 Completion of Treatment: Case Studies or A Little Bit of Everything Presented by Cherie Fulk February 25, 2015 Cherie Fulk
More informationTB Treatment Update. Dane County s TB Summit 2012 Randall Reves, MD, MSc Denver Metro Tuberculosis Control Program Denver Public Health Department
TB Treatment Update Dane County s TB Summit 2012 Randall Reves, MD, MSc Denver Metro Tuberculosis Control Program Denver Public Health Department Approach to a Patient Suspected of Having TB: AFB Smear
More informationIntroduction. Keywords drug development, drug-resistant tuberculosis, drug-susceptible tuberculosis, multidrug therapy
New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes Christian Lienhardt a, Andrew Vernon b and Mario C. Raviglione
More information